Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety and tolerability of RMC-6236 in adults with KRAS p.G12 mutant advanced solid tumors, KRAS p.G12C excluded.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Revolution Medicines, Inc.

Criteria

Inclusion Criteria:

• Histologically confirmed advanced solid tumor with KRAS p.G12A, KRAS p.G12D, KRAS p.G12R, KRAS p.G12S, or KRAS p.G12V mutations identified through deoxyribonucleic acid (DNA) sequencing.

• Received prior standard therapy appropriate for tumor type and stage

• Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

• Adequate organ function

Exclusion Criteria:

• Tumor harboring the KRAS p.G12C mutation

• Primary central nervous system (CNS) tumors

• Known or suspected leptomeningeal or brain metastases or spinal cord compression

• Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication

• History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy